{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:21:17Z","timestamp":1767676877548,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jagp.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T02:04:14Z","timestamp":1616119454000},"page":"1239-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults"],"prefix":"10.1016","volume":"29","author":[{"given":"Susmita","family":"Chandramouleeshwaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naba","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose N.","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne E.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair J.","family":"Flint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Mah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek K.","family":"Rajji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2021.03.002_bib0001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.sapharm.2019.05.020","article-title":"Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression","volume":"16","author":"Chatterjee","year":"2020","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.jagp.2021.03.002_bib0002","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jagp.2021.03.002_bib0003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jagp.2021.03.002_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jalz.2012.02.005","article-title":"Long-term anticholinergic use and the aging brain","volume":"9","author":"Cai","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jagp.2021.03.002_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/phar.2106","article-title":"Anticholinergics influence transition from normal cognition to mild cognitive impairment in older adults in primary care","volume":"38","author":"Campbell","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jagp.2021.03.002_bib0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ebmh.13.2.44","article-title":"Anticholinergic drugs increase the risk of cognitive decline and dementia in older people","volume":"13","author":"Cancelli","year":"2010","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.jagp.2021.03.002_bib0007","doi-asserted-by":"crossref","first-page":"k1315","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"361","author":"Richardson","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jagp.2021.03.002_bib0008","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/11317660-000000000-00000","article-title":"Effects of potent anticholinergics, sedatives and antipsychotics on postoperative mortality in elderly patients with hip fracture: a retrospective, population-based study","volume":"26","author":"Panula","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.12617","article-title":"Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis","volume":"80","author":"Ruxton","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jagp.2021.03.002_bib0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JAD-180353","article-title":"Anticholinergic burden and risk of stroke and death in people with different types of dementia","volume":"65","author":"Tan","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jagp.2021.03.002_bib0011","first-page":"225","article-title":"The cognitive impact of anticholinergics: a clinical review","volume":"4","author":"Campbell","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","article-title":"Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence","volume":"28","author":"Collamati","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.jagp.2021.03.002_bib0013","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00019442-200506000-00013","article-title":"Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia","volume":"13","author":"Chew","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2021.03.002_bib0014","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jgs.13988","article-title":"Association between anticholinergic load and frailty in community-dwelling older people","volume":"64","author":"Lampela","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40266-013-0104-x","article-title":"Prevalence and determinants of anticholinergic medication use in elderly dementia patients","volume":"30","author":"Sura","year":"2013","journal-title":"Drugs Aging"},{"issue":"Suppl 21","key":"10.1016\/j.jagp.2021.03.002_bib0016","first-page":"11","article-title":"Anticholinergic effects of medication in elderly patients","volume":"62","author":"Tune","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jagp.2021.03.002_bib0017","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0018","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archpsyc.60.2.198","article-title":"Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance","volume":"60","author":"Mulsant","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jagp.2021.03.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151084","article-title":"Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature","volume":"11","author":"Salahudeen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jagp.2021.03.002_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","article-title":"Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review","volume":"15","author":"Salahudeen","year":"2015","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jagp.2021.03.002_bib0021","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jgs.13206","article-title":"Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people","volume":"63","author":"Salahudeen","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0022","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40266-018-0549-z","article-title":"Anticholinergic drug burden tools\/scales and adverse outcomes in different clinical settings: a systematic review of reviews","volume":"35","author":"Welsh","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0023","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/jgs.12632","article-title":"Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline","volume":"62","author":"Kashyap","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0024","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40266-018-0584-9","article-title":"Association of anticholinergic drug burden with cognitive and functional decline over time in older inpatients: results from the CRIME Project","volume":"35","author":"Brombo","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/jcpt.12706","article-title":"Anticholinergic load negatively correlates with recovery of cognitive activities of daily living for geriatric patients after stroke in the convalescent stage","volume":"43","author":"Kose","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jagp.2021.03.002_bib0026","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archpsyc.1980.01780160063007","article-title":"Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects","volume":"37","author":"Tune","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jagp.2021.03.002_bib0027","first-page":"24","article-title":"A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice","volume":"36","author":"Carnahan","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jagp.2021.03.002_bib0028","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jagp.2014.09.009","article-title":"Small longitudinal study of serum anticholinergic activity and cognitive change in community-dwelling older adults","volume":"23","author":"Kashyap","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2021.03.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/2398212818820506","article-title":"Acetylcholine and cholinergic receptors","volume":"3","author":"Brown","year":"2019","journal-title":"Brain Neurosci Adv"},{"key":"10.1016\/j.jagp.2021.03.002_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12264-013-1406-z","article-title":"M1 muscarinic acetylcholine receptor in Alzheimer's disease","volume":"30","author":"Jiang","year":"2014","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.jagp.2021.03.002_bib0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jagp.2021.03.002_bib0032","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jagp.2021.03.002_bib0033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.vascn.2017.03.001","article-title":"An improved, high-efficiency assay for assessing serum anticholinergic activity using cultured cells stably expressing M1 receptors","volume":"86","author":"Nobrega","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.jagp.2021.03.002_bib0034","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3233\/JAD-200141","article-title":"Mulsant for the PACt-MD study group: design and rationale of the PACt-MD randomized clinical trial: prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in mild cognitive impairment and depression","volume":"76","author":"Rajji","year":"2020","journal-title":"J. Alzheimer's Disease"},{"key":"10.1016\/j.jagp.2021.03.002_bib0035","unstructured":"Rajji TK, Bowie CR, Herrmann N, et al: Design and rationale of the PACt-MD randomized clinical trial: prevention of Alzheimer's dementia with cognitive remediation plus transcranial direct current stimulation in mild cognitive impairment and depression. J. Alzheimers Dis. In Press;"},{"key":"10.1016\/j.jagp.2021.03.002_bib0036","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jamda.2008.11.005","article-title":"A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia","volume":"10","author":"Kolanowski","year":"2009","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0037","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40266-012-0044-x","article-title":"Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study","volume":"30","author":"Pasina","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0038","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jagp.2021.03.002_bib0039","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state - practical method for grading cognitive state of patients for clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatric Res"},{"key":"10.1016\/j.jagp.2021.03.002_bib0040","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0041","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40266-015-0321-6","article-title":"Central anticholinergic adverse effects and their measurement","volume":"32","author":"Lampela","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0042","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1532-5415.2009.02411.x","article-title":"Flaws in the serum anticholinergic activity assay: implications for the study of delirium","volume":"57","author":"Cox","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0043","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","article-title":"Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies","volume":"11","author":"Levey","year":"1991","journal-title":"J Neurosci"},{"key":"10.1016\/j.jagp.2021.03.002_bib0044","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2018.12.005","article-title":"M1 muscarinic receptors facilitate hippocampus-dependent cognitive flexibility via modulating GluA2 subunit of AMPA receptors","volume":"146","author":"Xiong","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jagp.2021.03.002_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2015.10.002","article-title":"Systematic review on the use of anticholinergic scales in poly pathological patients","volume":"62","author":"Villalba-Moreno","year":"2016","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.jagp.2021.03.002_bib0046","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bcpt.12140","article-title":"Anticholinergic drug burden in older people's brain - how well is it measured?","volume":"114","author":"Kersten","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jagp.2021.03.002_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bcpt.12140","article-title":"Anticholinergic drug burden in older people's brain - how well is it measured?","volume":"114","author":"Kersten","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jagp.2021.03.002_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2015.10.002","article-title":"Systematic review on the use of anticholinergic scales in poly pathological patients","volume":"62","author":"Villalba-Moreno","year":"2016","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.jagp.2021.03.002_bib0049","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1532-5415.2010.03307.x","article-title":"Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay","volume":"59","author":"Jakobsen","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0050","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/phar.1843","article-title":"Association of anticholinergic burden with cognitive impairment and health care utilization among a diverse ambulatory older adult population","volume":"36","author":"Campbell","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jagp.2021.03.002_bib0051","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/07853890.2016.1252053","article-title":"Drug Burden Index and change in cognition over time in community-dwelling older men: the CHAMP study","volume":"49","author":"Jamsen","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.jagp.2021.03.002_bib0052","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12603-016-0787-x","article-title":"Anticholinergic burden and functional status in older people with cognitive impairment: results from the regal project","volume":"21","author":"Boccardi","year":"2017","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0053","first-page":"14","article-title":"The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents","volume":"36","author":"Carnahan","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jagp.2021.03.002_bib0054","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pscychresns.2012.04.014","article-title":"Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia","volume":"204","author":"Wojtalik","year":"2012","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jagp.2021.03.002_bib0055","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jagp.2021.03.002_bib0056","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.psym.2013.04.004","article-title":"Assessing cognitive effects of anticholinergic medications in patients with coronary artery disease","volume":"55","author":"Lanctot","year":"2014","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jagp.2021.03.002_bib0057","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40266-013-0055-2","article-title":"Detailed cognitive function and use of drugs with anticholinergic properties in older people: a community-based cross-sectional study","volume":"30","author":"Uusvaara","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jagp.2021.03.002_bib0058","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/j.1532-5415.2008.02009.x","article-title":"Cumulative anticholinergic exposure is associated with poor memory and executive function in older men","volume":"56","author":"Han","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0059","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/npp.2010.104","article-title":"Modes and models of forebrain cholinergic neuromodulation of cognition","volume":"36","author":"Hasselmo","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jagp.2021.03.002_bib0060","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/archinternmed.2009.229","article-title":"Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study","volume":"169","author":"Carriere","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jagp.2021.03.002_bib0061","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.2004.02232.x","article-title":"Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study","volume":"59","author":"Lechevallier-Michel","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jagp.2021.03.002_bib0062","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/gerona\/glt192","article-title":"Long-term cognitive and functional effects of potentially inappropriate medications in older women","volume":"69","author":"Koyama","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jagp.2021.03.002_bib0063","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1532-5415.2011.03491.x","article-title":"Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study","volume":"59","author":"Fox","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2021.03.002_bib0064","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bcp.13734","article-title":"Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study","volume":"85","author":"Andre","year":"2019","journal-title":"Br J Clin Pharmacol"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748121002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748121002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:31:48Z","timestamp":1761021108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748121002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1064748121002608"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2021.03.002","relation":{},"ISSN":["1064-7481"],"issn-type":[{"type":"print","value":"1064-7481"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2021.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}